Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase I study of echinomycin.

R Pazdur1, C D Haas, L H Baker

  • 1Division of Hematology/Oncology, Wayne State University, Detroit, MI 48201.

Cancer Treatment Reports
|December 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External control arms in oncology: current use and future directions.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same journal

Rhabdomyolysis associated with high-dose cytarabine.

Cancer treatment reports·1987
Same journal

Acute laryngeal edema after single-dose irradiation and doxorubicin.

Cancer treatment reports·1987
Same journal

Timing may be a critical factor in drug therapy.

Cancer treatment reports·1987
Same journal

Prednimustine in advanced malignant melanoma: a phase II study.

Cancer treatment reports·1987
Same journal

Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

Cancer treatment reports·1987
Same journal

Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

Cancer treatment reports·1987
See all related articles

Echinomycin showed dose-limiting toxicity, including nausea and organ dysfunction, at high doses in advanced carcinoma patients. Phase II trials are feasible at 1200 micrograms/m2 weekly.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Echinomycin is an antitumor antibiotic.
  • Investigating Echinomycin's safety and efficacy in advanced cancers is crucial.

Purpose of the Study:

  • To determine the maximum tolerated dose (MTD) of Echinomycin.
  • To assess the safety and tolerability profile of Echinomycin in patients with advanced carcinoma.

Main Methods:

  • Administered Echinomycin weekly via 15-minute IV infusions for four doses.
  • Dose escalation from 60 to 1500 micrograms/m2.
  • Monitored for adverse events, including nausea, vomiting, anorexia, renal and hepatic dysfunction, and hematologic changes.

Main Results:

  • Dose-limiting toxicities (nausea, vomiting, anorexia, renal/hepatic dysfunction) observed at 1500 micrograms/m2.

Related Experiment Videos

  • Thrombocytopenia occurred in 15% of patients receiving >= 700 micrograms/m2, severe in 11%.
  • Leukopenia was rare and mild; allergic reactions were noted.

    • Conclusions:

    • The MTD was not reached within the tested dose range due to dose-limiting toxicities.
    • A weekly dose of 1200 micrograms/m2 is proposed as a feasible dose for Phase II trials.
    • Further investigation into Echinomycin's therapeutic potential in advanced cancers is warranted.